Florian Lordick
Florian Lordick
University Cancer Center Leipzig
Verified email at medizin.uni-leipzig.de - Homepage
Cited by
Cited by
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …
M Peeters, T Jay Price
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
G Folprecht, T Gruenberger, WO Bechstein, HR Raab, F Lordick, ...
The lancet oncology 11 (1), 38-47, 2010
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
F Lordick, K Ott, BJ Krause, WA Weber, K Becker, HJ Stein, S Lorenzen, ...
The lancet oncology 8 (9), 797-805, 2007
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ...
The lancet oncology 14 (6), 490-499, 2013
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer …
C Schuhmacher, S Gretschel, F Lordick, P Reichardt, W Hohenberger, ...
Journal of clinical oncology 28 (35), 5210, 2010
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
HA Wieder, BLDM Brucher, F Zimmermann, K Becker, F Lordick, A Beer, ...
Journal of Clinical Oncology 22 (5), 900-908, 2004
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Lordick, C Mariette, K Haustermans, R Obermannová, D Arnold
Annals of Oncology 27, v50-v57, 2016
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
K Ott, WA Weber, F Lordick, K Becker, R Busch, K Herrmann, H Wieder, ...
Journal of clinical oncology 24 (29), 4692-4698, 2006
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic …
MS Aapro, SM Grunberg, GM Manikhas, G Olivares, T Suarez, ...
Annals of oncology 17 (9), 1441-1449, 2006
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
K Ott, U Fink, K Becker, A Stahl, HJ Dittler, R Busch, H Stein, F Lordick, ...
Journal of clinical oncology 21 (24), 4604-4610, 2003
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer
E Van Cutsem, Y Kang, H Chung, L Shen, A Sawaki, F Lordick, J Hill, ...
J clin oncol 27 (18)(suppl), LBA4509, 2009
Oesophageal cancer
EC Smyth, J Lagergren, RC Fitzgerald, F Lordick, MA Shah, P Lagergren, ...
Nature reviews Disease primers 3 (1), 1-21, 2017
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer
C Rodel, T Liersch, RM Hermann, D Arnold, T Reese, M Hipp, A Furst, ...
Journal of Clinical Oncology 25 (1), 110-117, 2007
German S3-guideline" Diagnosis and treatment of esophagogastric cancer"
M Moehler, SE Al-Batran, T Andus, M Anthuber, J Arends, D Arnold, ...
Zeitschrift fur Gastroenterologie 49 (4), 461-531, 2011
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
F Lordick, B Luber, S Lorenzen, S Hegewisch-Becker, G Folprecht, E Wöll, ...
British journal of cancer 102 (3), 500-505, 2010
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of …
S Lorenzen, T Schuster, R Porschen, SE Al-Batran, R Hofheinz, ...
Annals of oncology 20 (10), 1667-1673, 2009
Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA …
Y Bang, H Chung, J Xu, F Lordick, A Sawaki, N Al-Sakaff, O Lipatov, ...
Journal of Clinical Oncology 27 (15_suppl), 4556-4556, 2009
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)
G Folprecht, T Gruenberger, W Bechstein, HR Raab, J Weitz, F Lordick, ...
Annals of oncology 25 (5), 1018-1025, 2014
The system can't perform the operation now. Try again later.
Articles 1–20